# PepGen (stock symbol: PEPG) Logo in transparent PNG and SVG formats

## PepGen Logo large

### PepGen Logo large Download PNG (47.91 KB)

![PepGen Logo large Download PNG (47.91 KB)](/img/orig/PEPG_BIG-cca0ee81.png)

### PepGen Logo large Download SVG (5.56 KB)

![PepGen Logo large Download SVG (5.56 KB)](/img/orig/PEPG_BIG-f3e90faf.svg)

## PepGen Logo icon format

### PepGen Logo icon format Download PNG (66.42 KB)

![PepGen Logo icon format Download PNG (66.42 KB)](/img/orig/PEPG-de400795.png)

### PepGen Logo icon format Download SVG (1.65 KB)

![PepGen Logo icon format Download SVG (1.65 KB)](/img/orig/PEPG-e515f311.svg)

## PepGen Logo large for dark backgrounds

### PepGen Logo large for dark backgrounds Download PNG (46.61 KB)

![PepGen Logo large for dark backgrounds Download PNG (46.61 KB)](/img/orig/PEPG_BIG.D-44e829ed.png)

### PepGen Logo large for dark backgrounds Download SVG (5.56 KB)

![PepGen Logo large for dark backgrounds Download SVG (5.56 KB)](/img/orig/PEPG_BIG.D-dc6d6277.svg)

## About PepGen

PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.

1. Website domain: pepgen.com
2. Employees: 40
3. Marketcap: $0.35 Billion USD


## Categories
- [x] ðŸ‡ºðŸ‡¸ United States
- [x] ðŸ’Š Pharmaceuticals
- [x] ðŸ§¬ Biotech
